A long-term prospective monitoring study of all patients with Pompe Disease. Evaluating natural history, treatment response, disease markers and novel outcome measures.
Pompe disease is a rare condition that causes muscle weakness and breathing difficulties because the body cannot break down certain sugars properly. While treatments exist to help replace the missing enzyme, doctors still need more information about how well they work over many years. This long-term monitoring study follows adults living with Pompe disease who are receiving standard approved therapies, such as Myozyme, Nexviadyme, or Pombiliti with Opfolda. Rather than testing an experimental drug, researchers will observe participants during routine clinic visits. Taking part involves regular health checks, including simple walking tests, muscle strength checks, breathing measurements, and routine blood and urine tests. The goal is to build a clearer picture of how Pompe disease changes over a lifetime and how current treatments support everyday mobility and general quality of life.
A colpo d'occhio
Di cosa tratta questo studio?
Pompe disease (also known as acid maltase deficiency or glycogen storage disease type II) is a rare genetic condition. In people with Pompe disease, the body lacks enough of a specific enzyme needed to break down a complex sugar called glycogen. Over time, this sugar builds up inside cells, causing damage to muscles throughout the body, particularly the muscles used for moving and breathing.
Several approved treatments are now available to help manage Pompe disease. These include enzyme replacement therapies like Myozyme and Nexviadyme, as well as newer combined treatments like Pombiliti and Opfolda. However, because Pompe disease is rare, doctors still need more evidence about how people respond to these treatments over long periods. This study is a Phase IV monitoring trial, which means it observes patients using approved treatments in ordinary clinical care rather than testing unproven experimental medicines.
By following patients over time, the research team aims to track natural disease changes, monitor how well medications preserve muscle and lung power, and test new ways to measure wellbeing. The information gathered will help specialist clinics provide better, more personalised care for people living with Pompe disease in the UK and worldwide.
Punti chiave
- A long-term study monitoring adults living with Pompe disease.
- Focuses on tracking muscle strength, breathing, and real-world response to approved treatments.
- Involves routine assessments such as walking tests, lung checks, and questionnaires.
- Does not require testing an unlicensed experimental medicine.
- Participation is voluntary and runs alongside your normal specialist clinic appointments.
Chi può essere idoneo?
This study is designed for adults aged 18 and over who have a confirmed diagnosis of Pompe disease (acid maltase deficiency). Both men and women can join.
Participants are typically people who are either receiving one of the approved medications for Pompe disease—such as Myozyme, Nexviadyme, or Pombiliti with Opfolda—or who are being monitored by a specialist metabolic team.
Your hospital doctor can check whether your diagnosis and current treatment plan fit the study requirements. Because this is an observational monitoring study, having other health conditions will not necessarily stop you from joining, provided you are able to complete the routine clinic assessments.
Questo studio potrebbe fare al caso tuo?
Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.
- I am aged 18 or older.
- I have a confirmed medical diagnosis of Pompe disease (glycogen storage disease type II).
- I am currently receiving or being considered for standard Pompe disease treatment.
- I am able to attend regular clinic appointments for health checks.
- I am willing to share test results and complete quality-of-life questionnaires.
Cosa comporta la partecipazione?
Taking part mainly involves having your health tracked during regular clinic appointments over an extended period. Because this is a long-term monitoring study, it will run for several years alongside your standard NHS care. You will continue taking your prescribed Pompe disease medication as directed by your specialist.
During your visits, the research team will carry out standard physical checks. These include timed walking and movement tests (such as seeing how far you can walk in six minutes or how easily you can stand from a chair), muscle strength checks, and breathing tests (measuring your lung power while sitting and lying down). You will also give routine blood and urine samples and complete short questionnaires about your daily energy, mobility, and quality of life. In some cases, tests to check heart function or sleep patterns may also be reviewed.
Rischi e benefici potenziali
Luoghi (1)
- —Non verificatoPaesi Bassi
Domande comuni
Will I have to try an experimental new drug?
No. This study monitors patients using approved treatments that are already licensed for Pompe disease, such as Myozyme, Nexviadyme, or Pombiliti and Opfolda.
Quanto dura lo studio?
This is a long-term follow-up study designed to track your health over several years as part of your regular ongoing hospital reviews.
Are the physical tests painful?
No. The tests involve simple walking tasks, breathing into a mouthpiece, and standard muscle checks. Some exercises may feel tiring, but you can rest whenever you need to.
Will taking part cost me anything?
No. The study assessments are done during clinical visits. Your standard treatment is provided through your specialist clinic, and taking part does not add treatment costs.
Posso abbandonare lo studio se cambio idea?
Yes. You can withdraw from the study at any point. You do not have to give a reason, and your routine medical treatment will continue as normal.
Come saperne di più
Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.
Discussione
Discussione della comunità
Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.